Bayer Baycol avoids class action
Executive Summary
Minneapolis federal court denies plaintiffs' motion for class action certification. Bayer had argued that possible claims would have comprised too many diverse and individual issues. Baycol settlements accelerated following initial favorable trial court decisions for Bayer (1"The Pink Sheet" May 12, 2003, p. 20). The company has settled more than 1,342 cases in the U.S. to date...
You may also be interested in...
Bayer’s Baycol Settlements Coming At Quicker Pace; 785 Suits Settled So Far
Bayer has seen the pace of Baycol-related settlements quicken following favorable decisions in the first two cases to come to trial, Finance Division Head Klaus Kühn said during Bayer's May 7 quarterly earnings call
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Pair Of Deaths Linked To Recalled Vyaire Medical Respiratory Devices
The US FDA has labelled a recall of more than 6 million Airlife respiratory support devices class I. The recall covers devices manufactured in 2017 or earlier that can fail to provide adequate ventilation.